If I remember correctly, Dr. Recknor had to go to the trail
If I remember correctly, Dr. Recknor had to go to the trail sites and get the data from them that had already been sent to Amarex. Because Amarex was not allowing Cytodyn access to the data, they went direct to the sources. It is the same data. Amarex was to populate the correct tables to justify and support the trail results for each section of dosing, efficacy, safety etc.. Amarex did not do that so the support of the data is what the problem likely was.
We don't know what literally was the diss-connect between what was int he BLA sections and what was collected from the trial sites, but my guess is that specific patient info, the test results collected and the trial outcome was not matched up so they could not say patient a with this background showed this result from the drug. I don't know this but this would be the only way a trial's data could be good, but the BLA un useable in my mind.
I i was the FDA, I would want to know the support for trial results more than i care how good the results are. If there is any integrity dis-connect, the whole data set can't be used. The FDA wants to triangulate 3+ datapoints so each part supports the other from more than one piece of data. Just like a journalist needs to verify their sources, drugs need to verify theirs.
I am tired of reading post that claim the data is garbage or everything is good, we just need to put stuff in the right cell of the spreadsheet. Neither is correct and there must be an impossible gap to bridge.
I do wonder, because i know the protocol changed many times, if the original protocol for combo was fine and later on we tried to add to the possible level of approval as we saw the data. This would likely create a situation where what was being collected does not match with what the endpoint needed. I don't know if the receptor occupancy test (which was added later) or if it was the investigational mono trial that screwed it all up. Either way, Amarex did not run this right and Cytodyn paid them to do a job they claimed they could do.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...
Continue Reading
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding the Impact of Nonfarm Payrolls Report The latest statistics from the Nonfarm Payrolls report have presented some eye-opening results in employment figures. The total number of employed individuals, excluding agriculture and certain other employment sectors, has shot up to 256,000. This number has not only exceeded expectations but has also painted a brighter...
Continue Reading
WuXi Biologics Reports Impressive Interim Results WuXi Biologics (stock code: 2269.HK), a prominent global Contract Research, Development and Manufacturing Organization (CRDMO), has showcased robust performance in its interim results for the first half of 2025. The data released illustrates a remarkable 16.1% year-over-year increase in revenue, reaching a significant RMB...
Continue Reading
Trulieve Cannabis Corp. Receives Conditional Approval in Texas Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a prominent leader in the cannabis industry, is thrilled to announce that it has received conditional approval for a Dispensing Organization license from the Texas Department of Public Safety. This significant milestone allows Trulieve TX, Inc. to engage in...
Continue Reading
Understanding Alliance Witan PLC's Net Asset Value Alliance Witan PLC is notable in the investment management arena, focusing on delivering substantial long-term returns. Investors pay close attention to the company's Net Asset Value (NAV) as it gives insights into the company’s financial health and asset valuation. Recently, Alliance Witan PLC provided an update...
Continue Reading
Introducing Getac's Advanced B360 and B360 Pro Laptops Getac Technology Corporation has officially launched the next generation of rugged laptops, the B360 and B360 Pro. These devices are engineered to withstand the toughest conditions while offering advanced AI-ready technology. Featuring the latest Intel® Core Ultra Series 2 processors and Intel® AI Boost technology,...
Continue Reading